Gallbladder NeoplasmsCRGGCNCT04140552
Chinese Research Group of Gallbladder Cancer
An observational study of Gallbladder Neoplasms, run by Shanghai Jiao Tong University School of Medicine at 55 sites in China.
Trial summary
The Chinese Research Group of Gallbladder Cancer (CRGGC) is a retrospective multicenter registry cohort, collecting electronic medical records of patients diagnosed with gallbladder cancer from hospitals in collaboration. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gallbladder Neoplasms
- How many people
- 10,000 participants
- Where
- 55 sitesChina
- Study dates
- 1 Jan 2008to 31 Dec 2025
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients from 2008 to 2020 diagnosed with gallbladder cancer in collaborated hospitals in China.
Who may be able to join
- Patients with at least clinical diagnosis of gallbladder cancer, including C23.9 and part of C24.0 (cystic duct cancer).
- Patients with accessible electronic medical record
Who cannot join
- Patients with undetermined primary site of cancer.
Trial locations and contacts
55 sites in 1 country.
55 sites in 1 country
China55 sites, 55 recruiting
- Recruiting
Baotou City Central Hospital
Baotou, Inner Mongolia, 014040
Mingzhang Li, MD
- Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004
Jianguang Jia, MD
- Recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021
Yajun Geng, MD
- Recruiting
China-Japan Union Hospital of Jilin University
Changchun, Jilin, 130033
Hong Cao, MD
- Recruiting
The Second Hospital of Jilin University
Changchun, Jilin, 130041
Xuewen Zhang, MD
- Recruiting
People's Hospital of Hunan Province
Changsha, Hunan, 410001
Changjun Liu, MD
- Recruiting
Changshu No.1 People's Hospital
Changshu, Jiangsu, 215500
Jianfeng Gu, MD
- Recruiting
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, 046000
Buqiang Wu, MD
- Recruiting
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, 213003
Chunfu Zhu, MD
- Recruiting
The First Hospital of Lanzhou University
Gansu, Lanzhou, 730000
Xun Li, MD
- Recruiting
The Second Affiliated Hospital of Zhejiang University School of medicine
Hangzhou, Zhejiang, 310009
Jinhui Zhu, MD
- Recruiting
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, 310020
Defei Hong, MD
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022
Xinbao Wang, MD
- Recruiting
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150009
Bei Sun, MD
- Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081
Bing Li, 150081
- Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150086
Yunfu Cui, MD
- Recruiting
Anhui Provincial Hospital
Hefei, Anhui, 230001
Lianxin Liu, MD
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022
Yeben Qian, MD
- Recruiting
Huzhou Central Hospital
Huzhou, Zhejiang, 313000
Weilong Cai, MD
- Recruiting
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650031
Kunhua Wang, MD
- Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006
Xiaoliang Chen, MD
- Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330008
Lu Fang, MD
- Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330019
Linhui Zheng, MD
- Recruiting
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008
Yudong Qiu, MD
- Recruiting
The First People's Hospital of Nantong
Nantong, Jiangsu, 226001
Hong Zang, MD
- Recruiting
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226021
Peng Wang, MD
- Recruiting
Nantong Tumor Hospital
Nantong, Jiangsu, 226361
Hongyu Cai, MD
- Recruiting
Ningbo First Hospital
Ningbo, Zhejiang, 315010
Zhiping Zhang, MD
- Recruiting
Yinzhou Hospital Affiliated to Medical School of Ningbo University
Ningbo, Zhejiang, 315040
Kejun Hua, MD
- Recruiting
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032
Houbao Liu, MD
- Recruiting
Putuo District People's Hospital of Shanghai
Shanghai, Shanghai Municipality, 200062
Jiahua Yang, MD
- Recruiting
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080
Junmin Xu, MD
- Recruiting
Xinhua Hospital
Shanghai, Shanghai Municipality, 200092
Yingbin Liu, 13918803900, laoniulyb@163.com
- Recruiting
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, 200438
Xiaoqing Jiang
- Recruiting
Central Hospital of Minhang District
Shanghai, Shanghai Municipality, 201100
Longhua Rao, MD
- Recruiting
Shanghai Pudong Hospital
Shanghai, Shanghai Municipality, 201399
Xiaoping Yang, MD
- Recruiting
Shanghai Fengxian District Central Hospital
Shanghai, Shanghai Municipality, 201499
Xueli Zhang, MD
- Recruiting
Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 202150
Zhewei Fei, MD
- Recruiting
Shaoxing People's Hospital
Shaoxing, Zhejiang, 312000
Feng Tao, MD
- Recruiting
Shaoxing Second Hospital
Shaoxing, Zhejiang, 312000
Zaiyang Zhang, MD
- Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004
Chaoliu Dai, MD
- Recruiting
The Second Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, 215004
Xiaoming Ma, MD
- Recruiting
The First People's Hospital of Taicang
Taicang, Jiangsu, 215400
Yi Wang, MD
- Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001
Jiansheng Liu, MD
- Recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013
Xueyi Dang, MD
- Recruiting
Tianjin Medical University Cancer Hospital
Tianjin, Tianjin Municipality, 300060
Jihui Hao, MD
- Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054
Wei Han, MD
- Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325015
Mengtao Zhou, MD
- Recruiting
Wuxi Second People's Hospital
Wuxi, Jiangsu, 214002
Lei Wang, MD
- Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061
Chang Liu, MD
- Recruiting
Qinghai Provincial People's Hospital
Xining, Qinghai, 810007
Haihong Zhu, MD
- Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221006
Jian Hong, MD
- Recruiting
Xuzhou Central Hospital
Xuzhou, Jiangsu, 221009
Yuzhen Xu, MD
- Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, 450003
Yawei Hua, MD
- Recruiting
The Fifth Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
Xiaoyong Li, MD
About this study
The Chinese Research Group of Gallbladder Cancer (CRGGC) is a retrospective multicenter registry cohort, collecting electronic medical records of patients diagnosed with gallbladder cancer from hospitals in collaboration.
Read the detailed description
The objectives of the CRGGC are as follows:
- To study the current diagnosis and treatment of gallbladder cancer in China.
- To clarify the prognostic role of debated risk factors associated with gallbladder cancer.
- To improve the accurate staging of gallbladder cancer.
- To standardize the treatment with gallbladder cancer.
- Conditions
- Gallbladder Neoplasms
- Keywords
- gallbladder neoplasms, gallbladder cancer
- Medical subject headings
- Gallbladder Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
The overall survival data were defined by (date of death) - (date of first diagnosis). The survival status of patients were retrieved from follow-up.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2019
- Study start1 Jan 2008
- Primary completion31 Dec 2022 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Gallbladder NeoplasmsStudies of the same condition, open and under way.
- More trials run by Shanghai Jiao Tong University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital of Bengbu Medical University, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi No. 2 People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Province Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Kunming Medical University, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital
- Responsible party
- Principal investigator, Yingbin Liu, MD, PhD, FACS, Shanghai Jiao Tong University School of Medicine
- Investigators
- Yingbin Liu, MD, PhD, Principal investigator, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04140552
- Sponsor's protocol ID
- CRGGC_LYB_2019
- Acronym
- CRGGC
- Status last verified
- Jun 2021
- First submitted
- 24 Oct 2019
- Last updated
- 30 Jun 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plan for IPD access is scheduled.
Publications
Li L, Ren T, Liu K, Li ML, Geng YJ, Yang Y, Li HF, Li XC, Bao RF, Shu YJ, Weng H, Gong W, Lau WY, Wu XS, Liu YB. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Front Oncol. 2021 Jun 29;11:692647. doi: 10.3389/fonc.2021.692647. eCollection 2021.
PubMed 34268122Ren T, Li Y, Zhang X, Geng Y, Shao Z, Li M, Wu X, Wang XA, Liu F, Wu W, Shu Y, Bao R, Gong W, Dong P, Dang X, Liu C, Liu C, Sun B, Liu J, Wang L, Hong D, Qin R, Jiang X, Zhang X, Xu J, Jia J, Yang B, Li B, Dai C, Cao J, Cao H, Tao F, Zhang Z, Wang Y, Jin H, Cai H, Fei Z, Gu J, Han W, Feng X, Fang L, Zheng L, Zhu C, Wang K, Zhang X, Li X, Jin C, Qian Y, Cui Y, Xu Y, Wang X, Liu H, Hua Y, Liu C, Hao J, Wang C, Li Q, Li X, Liu J, Li M, Qiu Y, Wu B, Zheng J, Chen X, Zhu H, Hua K, Yan M, Wang P, Zang H, Ma X, Hong J, Liu Y. Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. BMJ Open. 2021 Feb 16;11(2):e038634. doi: 10.1136/bmjopen-2020-038634.
PubMed 33593763
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chinese Research Group of Gallbladder Cancer
- ClinicalTrials.gov ID
- NCT04140552
- Acronym / sponsor ID
- CRGGC / CRGGC_LYB_2019
- Conditions
- Gallbladder Neoplasms
- Keywords
- gallbladder neoplasms, gallbladder cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Shanghai Jiao Tong University School of MedicineUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital of Bengbu Medical University, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi No. 2 People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Province Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Kunming Medical University, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital
- Study start
- 1 Jan 2008 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 28 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Chinese Research Group of Gallbladder Cancer (CRGGC) is a retrospective multicenter registry cohort, collecting electronic medical records of patients diagnosed with gallbladder cancer from hospitals in collaboration.
Detailed description
The objectives of the CRGGC are as follows:
- To study the current diagnosis and treatment of gallbladder cancer in China.
- To clarify the prognostic role of debated risk factors associated with gallbladder cancer.
- To improve the accurate staging of gallbladder cancer.
- To standardize the treatment with gallbladder cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients from 2008 to 2020 diagnosed with gallbladder cancer in collaborated hospitals in China.
Key inclusion criteria (2 listed)
- Patients with at least clinical diagnosis of gallbladder cancer, including C23.9 and part of C24.0 (cystic duct cancer).
- Patients with accessible electronic medical record
Key exclusion criteria (1 listed)
- Patients with undetermined primary site of cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival
Time frame: 5 years
The overall survival data were defined by (date of death) - (date of first diagnosis). The survival status of patients were retrieved from follow-up.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2021.
- Derived from this study: PubMed 34268122Li L, Ren T, Liu K, Li ML, Geng YJ, Yang Y, Li HF, Li XC, Bao RF, Shu YJ, Weng H, Gong W, Lau WY, Wu XS, Liu YB. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Front Oncol. 2021 Jun 29;11:692647. doi: 10.3389/fonc.2021.692647. eCollection 2021.
- Derived from this study: PubMed 33593763Ren T, Li Y, Zhang X, Geng Y, Shao Z, Li M, Wu X, Wang XA, Liu F, Wu W, Shu Y, Bao R, Gong W, Dong P, Dang X, Liu C, Liu C, Sun B, Liu J, Wang L, Hong D, Qin R, Jiang X, Zhang X, Xu J, Jia J, Yang B, Li B, Dai C, Cao J, Cao H, Tao F, Zhang Z, Wang Y, Jin H, Cai H, Fei Z, Gu J, Han W, Feng X, Fang L, Zheng L, Zhu C, Wang K, Zhang X, Li X, Jin C, Qian Y, Cui Y, Xu Y, Wang X, Liu H, Hua Y, Liu C, Hao J, Wang C, Li Q, Li X, Liu J, Li M, Qiu Y, Wu B, Zheng J, Chen X, Zhu H, Hua K, Yan M, Wang P, Zang H, Ma X, Hong J, Liu Y. Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. BMJ Open. 2021 Feb 16;11(2):e038634. doi: 10.1136/bmjopen-2020-038634.
- Individual participant dataSharing planned: No. No plan for IPD access is scheduled.
Related trials for Gallbladder Neoplasms
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Not yet recruitingPhase 3
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Biliary Tract Cancer, Cholangiocarcinoma
Recruiting
Distance-Based Exercise to Preserve Function and Prevent Disability
Localized Malignant Solid Neoplasm, Anal Cancer
RecruitingPhase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid Tumors, HER2 Mutation
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yingbin Liu, MD, PhD principal investigator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
55 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gallbladder Neoplasms, run by Shanghai Jiao Tong University School of Medicine at 55 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 55 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yingbin Liu, MD, PhD (+8613918803900, laoniulyb@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04140552, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2021.